Statement of Retraction: Dual approach utilizing self microemulsifying technique and novel P-gp inhibitor for effective delivery of taxanes (Journal of Microencapsulation, (2012), 29, 6, (583-595), 10.3109/02652048.2012.668959);Dual approach utilizing self microemulsifying technique and novel P-gp inhibitor for effective delivery of taxanes

Journal of Microencapsulation

Volumn 29, Issue 6, 2012, Pages 583-595

  Chaurasiya, Akash ^a,b   Singh, Ajeet K ^c   Jain, Gaurav K ^a   Warsi, Musarrat H ^a   Sublet, Emmanuelle ^b,d   Ahmad, Farhan J ^a   Borchard, Gerrit ^b,d   Khar, Roop K ^a  

^a HAMDARD UNIVERSITY   (India)

^b UNIVERSITY OF GENEVA   (Switzerland)

^c Matrix Laboratories Limited   (India)

^d Parc d'Affaires International   (France)

Author keywords

Caco 2 cells; Cancer; in vitro models; Microemulsion; Oral drug delivery; P glycoprotein

Indexed keywords

CASTOR OIL; CORN OIL; CYCLOSPORIN A; DIETHYLENE GLYCOL MONOETHYL ETHER; DOCETAXEL; ELACRIDAR; MACROGOL 3000; OCTANOIC ACID; OLEIC ACID; OLIVE OIL; PACLITAXEL; PROPYLENE GLYCOL; RHODAMINE 123; RITONAVIR; SAQUINAVIR; SOYBEAN OIL;

ARTICLE; CELL MEMBRANE PERMEABILITY; CONFOCAL LASER MICROSCOPY; CONTROLLED STUDY; DRUG BIOAVAILABILITY; DRUG DELIVERY SYSTEM; DRUG FORMULATION; DRUG PENETRATION; DRUG SOLUBILITY; DRUG STABILITY; DRUG UPTAKE; HUMAN; HUMAN CELL; HYDROPHILICITY; IN VITRO STUDY; IN VIVO STUDY; INTESTINE EPITHELIUM; IONIC STRENGTH; LIPOPHILICITY; MICROEMULSION; PARTICLE SIZE; PH; QUALITATIVE ANALYSIS; QUANTITATIVE ANALYSIS; SELF MICROEMULSIFYING DRUG DELIVERY SYSTEM; THERMODYNAMICS;

EID: 84865448770     PISSN: 02652048     EISSN: 14645246     Source Type: Journal    
DOI: 10.1080/02652048.2020.1864953     Document Type: Erratum

References (52)

1. Cao Y, Marra AY, Anderson BD. Predictive relationships for the effects of triglyceride ester concentration and water uptake on solubility and partitioning of small molecules into lipid vehicles. J Pharm Sci, 2004;93:2768-79. (Pubitemid 39506627)
2. Chervinsky DS, Brecher ML, Hoelcle MJ. Cremophor-EL enhances taxol efficacy in a multi-drug resistant C1300 neuroblastoma cell line. Anticancer Res, 1993;13:93-6. (Pubitemid 23118201)
3. Ciccolini J, Catalin J, Blachon MF, Durand A. Rapid high-performance liquid chromatographic determination of docetaxel (Taxotere) in plasma using liquid-liquid extraction. J Chrom B Biomed Sci Appl, 2001;759:299-306. (Pubitemid 32575290)
4. Constantinides PP. Lipid microemulsions for improving drug dissolution and oral absorption: Physical and biopharmaceutical aspects. Pharm Res, 1995;12:1561-72. (Pubitemid 26005509)
5. Craig DQM, Barker SA, Banning D, Booth SW. An investigation into the mechanisms of self-emulsification using particle size analysis and low frequency dielectric spectroscopy. Int J Pharm, 1995;114:103-10. (Pubitemid 24377034)
6. Dantzig AH, Shepard RL, Law KL, Tabas L, Pratt S, Gillespie JS, Binkley SN, Kuhfeld MT, Starling JJ, Wrighton SA. Selectivity of the multidrug resistance modulator, LY335979, for P-glycoprotein and effect on cytochrome P-450 activities. J Pharmacol Exp Ther, 1999;290:854-62. (Pubitemid 29344586)
7. Dintaman JM, Silverman JA. Inhibition of P-glycoprotein by D-alpha-tocopheryl polyethylene glycol 1000 succinate (TPGS). Pharm Res, 1999;16:1550-6. (Pubitemid 29510551)
8. Gao P, Rush BD, Pfund WP, Huang T, Bauer JM, Morozowich W, Kuo MS, Hageman MJ. Development of a supersaturable SEDDS (S-SEDDS) formulation of paclitaxel with improved oral bioavailability. J Pharm Sci, 2003;92:2386-98. (Pubitemid 37484765)
9. Green H, Soderkvist P, Rosenberg P, Mirghani RA, Rymark P, Lundqvist EA, Peterson C. Pharmacogenetic studies of paclitaxel in the treatment of ovarian cancer. Basic Clin Pharmacol Toxicol, 2009;104:130-7.
10. Gursoy N, Garrigue JS, Razafindratsita A, Lambert G, Benita S. Excipient effects on in-vitro cytotoxicity of a novel paclitaxel self-emulsifying drug delivery system. J Pharm Sci, 2003;92:2411-18. (Pubitemid 37484767)
11. Gursoy RN, Benita S. Self-emulsifying drug delivery systems (SEDDS) for improved oral delivery of lipophilic drugs. Biomed Pharmacother, 2004;58:173-82. (Pubitemid 38479922)
12. Hyafil F, Vergely C, Vignaud PD, Perret TG. In vitro and in vivo reversal of multidrug resistance by GF120918, an acridonecarboxamide derivative. Cancer Res, 1993;53:4595-602.
13. Khoo SM, Humberstone AJ, Porter CJH, Edwards GA, Charman WN. Formulation design and bioavailability assessment of lipidic selfemulsifying formulations of halofantrine. Int J Pharm, 1998
14. :155-64.
15. Lipinski CA. Drug-like properties and the causes of poor solubility and poor permeability. J Pharmacol Toxicol Methods, 2000;44:235-49. (Pubitemid 32239479)
16. Lipinski CA, Lombardo F, Dominy BW, Feeney PJ. Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings. Adv Drug Del Rev, 1997; 23:3-25. (Pubitemid 27046991)
17. MacGregor KJ, Embleton JK, Lacy JE, Perry EA, Solomon LJ, Seager H. Influence of lipolysis on drug absorption from the gastrointestinal tract. Adv Drug Del Rev, 1997;25:33-46. (Pubitemid 27107789)
18. Maliepaard M, Gastelen MAV, Tohgo A, Hausheer FH, Waardenburg RCV, Jong LAD, Pluim D, Beijnen JH, Schellens JH. Circumvention of breast cancer resistance protein (BCRP)-mediated resistance to camptothecins in vitro using non-substrate drugs or the BCRP inhibitor GF120918. Clin Cancer Res, 2001;7:935-41. (Pubitemid 32708732)
19. Malingré MM, Beijnen JH, Rosing H, Koopman FJ, Jewell RC, Paul EM, Huinink WWTB, Schellens JHM. Co-administration of GF120918 significantly increases the systemic exposure to oral paclitaxel in cancer patients. Br J Cancer, 2001a;84:42-7. (Pubitemid 32102502)
20. Malingré MM, Beijnen JH, Schellens JHM. Oral delivery of taxanes. Invest New Drug, 2001b;19:155-62. (Pubitemid 32423720)
21. Malingré MM, Richel DJ, Beijnen JH, Rosing H, Koopman FJ, Huinink WWTB, Schot ME, Schellens JHM. Coadministration of cyclosporine strongly enhances the oral bioavailability of docetaxel. J Clin Oncol, 2001c;19:1160-6. (Pubitemid 32176294)
22. Martena B, Pfeuffer M, Schrezenmeir J. Medium-chain triglycerides. Int Dairy J, 2006;16:1374-82. (Pubitemid 44331591)
23. Mohammadi A, Esmaeili F, Dinarvand R, Atyabi F, Walker RB. Development and validation of a stability-indicating method for the quantitation of paclitaxel in pharmaceutical dosage forms. J Chrom Sci, 2009;47:599-604.
24. Newman MJ, Rodarte JC, Benbatoul KD, Romano SJ, Zhang C, Krane S, Moran EJ, Uyeda RT, Dixon R, Guns ES, et al. Discovery and characterization of OC144-093, a novel inhibitor of P-glycoprotein mediated multidrug resistance. Cancer Res, 2000;60:2964-72. (Pubitemid 30395822)
25. Overmoyer B. Options for the treatment of patients with taxane-refractory metastatic breast cancer. Clin Breast Cancer, 2008;8:S61-S70.
26. Perloff MD, Moltke LLV, Stormer E, Shader RI, Greenblatt DJ. Saint John's wort: An in vitro analysis of P-glycoprotein induction due to extended exposure. Br J Pharmacol, 2001;134:1601-8. (Pubitemid 34038092)
27. Pouton CW. Self-emulsifying drug delivery systems: Assessment of the efficiency of emulsification. Int J Pharm, 1985;27:335-48. (Pubitemid 16218683)
28. Pouton CW. Formulation of self-microemulsifying delivery system. Adv Drug Del Rev, 1997;25:47-58.
29. Pouton CW. Lipid formulation for oral administration of drugs: Non-emulsifying, self-emulsifying and self-microemulsifying drug delivery systems. Eur J Pharm Sci, 2000;11:S93-8.
30. Raymond CR, Paul JS, Paul JW. 2003. Handbook of pharmaceutical excipients. Washington, DC, USA: Pharmaceutical Press and American Pharmaceutical Association. Roe M, Folkes A, Ashworth P, Brumwell J, Chima L, Hunjan S, Pretswell I, Dangerfield W, Ryder H, Charlton P. Reversal of P-glycoprotein mediated multidrug resistance by novel anthranilamide derivatives. Bioorg Med Chem Lett, 1999;9:595-600.
31. Roger E, Lagarce F, Garcion E, Benoit JP. Lipid nanocarriers improve paclitaxel transport throughout human intestinal epithelial cells by using vesicle-mediated transcytosis. J Cont Rel, 2009;140:174-81.
32. Roger E, Lagarce F, Garcion E, Benoit JP. Reciprocal competition between lipid nanocapsules and P-gp for paclitaxel transport across Caco-2 cells. Eur J Pharm Sci, 2010;40:422-9.
33. Rowinsky EK, Donehower RC. Paclitaxel (taxol). N Engl J Med, 1995;332:1004-14.
34. Saremi S, Atyabi F, Akhlaghi SP, Ostad SN, Dinarvand R. Thiolated chitosan nanoparticles for enhancing oral absorption of docetaxel: Preparation, in vitro and ex vivo evaluation. Int J Nanomed, 2011;12:119-28.
35. Schittenhelm MM, Kollmannsberger C, Oechsle K, Harlow A, Morich J, Honecker F, Kurek R, Storkel S, Kanz L, Corless CL, et al. Molecular determinants of response to matuzumab in combination with paclitaxel for patients with advanced non-small cell lung cancer. Mol Cancer Ther, 2009;8:481-9.
36. Shen H, Zhong M. Preparation and evaluation of self-microemulsifying drug delivery systems (SMEDDS) containing atorvastatin. J Pharm Pharmacol, 2006;58:1183-91. (Pubitemid 44329099)
37. Singh AK, Chaurasiya A, Awasthi A, Mishra G, Asati D, Khar RK, Mukherjee R. Oral bioavailability enhancement of exemestane from self-microemulsifying drug delivery system (SMEDDS). AAPS Pharm Sci Tech, 2009a;10:906-16.
38. Singh AK, Chaurasiya A, Jain GK, Awasthi A, Asati D, Mishra G, Khar RK, Mukherjee R. High performance liquid chromatography method for the pharmacokinetic study of bicalutamide SMEDDS and suspension formulations after oral administration to rats. Talanta, 2009b;78:1310-14.
39. Singla AK, Garg A, Aggarwal D. Paclitaxel and its formulations. Int J Pharm, 2002;235:179-92. (Pubitemid 34185449)
40. Storm G, Belliot SO, Daemen T, Lasic DD. Surface modification of nanoparticles to oppose uptake by the mononuclear phagocyte system. Adv Drug Del Rev, 1995;17:31-48.
41. Tansan S, Koc Y, Aydin H, Urbano G, McCaffrey R. Augmentation of vincristine cytotoxicity by megestrol acetate. Cancer Chemother Pharmacol, 1997;39:333-40. (Pubitemid 27047478)
42. Teodori E, Dei S, Scapecchi S, Gualtieri F. The medicinal chemistry of multidrug resistance (MDR) reversing drugs. Farmaco, 2002;57:385-415. (Pubitemid 34451020)
43. Terwogt JMM, Malingré MM, Beijnen JH, Huinink WWTB, Rosing H, Koopman FJ, Tellingen OV, Swart M, Schellens JH. Co-administration of oral cyclosporine A enables oral therapy with paclitaxel. Clin Cancer Res, 1999;5:3379-84.
44. Thomas H, Coley HM. Overcoming multidrug resistance in cancer: An update on the clinical strategy of inhibiting P-glycoprotein. Cancer Contr, 2003;10:159-62.
45. Troutman MD, Thakker DR. Rhodamine 123 requires carrier-mediated influx for its activity as a P-glycoprotein substrate in Caco-2 cells. Pharm Res, 2003;20:1192-9. (Pubitemid 36951844)
46. Tsallas A, Jackson J, Burt H. The uptake of paclitaxel and docetaxel into ex vivo porcine bladder tissue from polymeric micelle formulations. Cancer Chemother Pharmacol, 2009;68:431-44.
47. Walle T. Assays of CYP2C8- and CYP3A4-mediated metabolism of taxol in vivo and in vitro. Methods Enzymol, 1996;272:145-51. (Pubitemid 26299877)
48. Wallstab A, Koester M, Bohme M, Keppler D. Selective inhibition of MDR1 P-glycoprotein-mediated transport by the acridone carboxamide derivative GG918. Br J Cancer, 1999;79:1053-60. (Pubitemid 29087875)
49. Woo JS, Lee CH, Shim CK, Hwang SJ. Enhanced oral bioavailability of paclitaxel by coadministration of the P-glycoprotein inhibitor KR30031. Pharm Res, 2003;20:24-30. (Pubitemid 36152913)
50. Yang S, Gursoy RN, Lambert G, Benita S. Enhanced oral absorption of paclitaxel in a novel self-microemulsifying drug delivery system with or without concomitant use of P-glycoprotein inhibitors. Pharm Res, 2004;21:261-70. (Pubitemid 38221971)
51. Yin YM, Cui FD, Mu CF, Choi MK, Kim JS, Chung SJ, Shim CK, Kim DD. Docetaxel microemulsion for enhanced oral bioavailability: Preparation and in vitro and in vivo evaluation. J Cont Rel, 2009;140:86-94.
52. Zuylen LV, Nooter K, Sparreboom A, Verweij J. Development of multidrugresistance convertors: Sense or nonsense? Invest New Drugs, 2000;18:205-20. (Pubitemid 30599141)